View all the latest information in myeloproliferative neoplasms, arranged by trials and clinical studies. Listed below are recently added trial updates.
5-year results from the PROUD-PV and CONTINUATION-PV studies
Ropeginterferon alfa-2b is a novel pegylated recombinant interferon, approved in the EU as monotherapy for the treatment of adults with...
Ropeginterferon alfa-2b is effective and safe in patients older than 60 years with PV
As discussed in our last editorial theme, the pegylated forms of interferon-alpha improve treatment compliance...
European Commission approves fedratinib for the treatment of myelofibrosis
Fedratinib, a pyrimidine-based JAK2 and FLT3 inhibitor, has been granted approval for marketing authorization from the...
Fedratinib in myelofibrosis
Fedratinib is a pyrimidine-based Janus kinase 2 (JAK2) inhibitor currently licenced by the U.S. Food and Drug Administration (FDA) for the treatment of adults with...
Novel agents to treat MF with suboptimal response to ruxolitinib: Long-term outcome with momelotinib
Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway dysregulation is...
SIMPLIFY-1+2 trial: What is the long-term benefit of momelotinib treatment in R/R MF?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to Ruben...
What do the preliminary results of the MANIFEST trial say about CPI-0610 in treating MF?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to...
MANIFEST phase II study of ruxolitinib and CPI-0610 in patients with myelofibrosis: An update from Arms 2 and 3
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the...